证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |----------------------|------------------------------|-------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | ☑ 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓 | | 申万宏源、长城证券、弘则弥道研究、北京瑞翰资产、深圳沃伯 | | 名 | | 格投资控股、深圳广义资产、深圳东晟融通资产、深圳海富凌资 | | | | 本、深圳兰山骏德投资、深圳易金投资、银泰证券、深圳鹏万投 资、潮商投资、中山证券、森 ...

证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |----------------------|-----------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | ☑ 其他 | （深圳辖区上市公司投资者集体接待日活动） | | 参与单位名称及人员姓 | 通过"全景路演"（ | http://rs.p5w.net/ ）参与 2022 年深圳辖区上市 | | 名 | 公司投资者集体接待日活动的投资者 | | | 时间 | 2022 年 11 月 9 日 16 | ： 30-17 ： 30 | | 地点 | "全景路演"（ | http://rs.p5w.net/ ） | | 上市公 ...

Financial Performance - The company's revenue for Q3 2022 was ¥10,834,403,428.71, an increase of 2.82% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥18,162,405.63, a decrease of 75.28% year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥14,652,414.34, down 75.88% from the previous year[7]. - Total operating revenue for the current period is ¥28,955,751,861.94, a decrease of 5.93% from ¥30,775,630,066.91 in the previous period[29]. - Net profit for the current period is ¥218,156,601.74, a decline of 37.94% compared to ¥351,745,607.06 in the previous period[29]. - Basic earnings per share for the current period is ¥0.0480, down from ¥0.0777 in the previous period[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥36,745,760,034.24, a decrease of 2.28% from the end of the previous year[7]. - As of September 30, 2022, the company's total assets amounted to RMB 36,745,760,034.24, a decrease from RMB 37,603,849,419.61 at the beginning of the year[19]. - The total liabilities amounted to RMB 30,877,441,775.55, compared to RMB 31,616,610,446.47 at the beginning of the year[22]. - The total liabilities amount to ¥29,347,901,341.81, down from ¥30,295,590,943.09 in the previous period[29]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥631,812,732.98, a decrease of 44.12% compared to the previous year[7]. - The net cash flow from operating activities for Q3 2022 was ¥631,812,732.98, a decrease from ¥1,130,606,278.79 in Q3 2021, indicating a decline of approximately 44.2%[35]. - Total cash inflow from operating activities was ¥2,324,209,213.98, while cash outflow was ¥32,496,592,193.40, resulting in a significant cash outflow[35]. - The ending balance of cash and cash equivalents was ¥359,743,994.20, down from ¥1,490,498,412.18 at the beginning of the period, reflecting a decrease of approximately 75.8%[35]. Investments and Financing - Long-term borrowings increased by 37.26% compared to the beginning of the year, indicating an increase in long-term financing[13]. - The company reported a total cash inflow from financing activities of ¥17,350,468,225.70 in Q3 2021, indicating a year-over-year decrease of approximately 43.1%[35]. - Cash inflow from financing activities totaled ¥9,857,263,109.04, while cash outflow was ¥10,685,481,618.36, leading to a net cash flow of -¥828,218,509.32[35]. Operational Changes - The company is planning a significant asset restructuring and mixed ownership reform, with due diligence completed and discussions ongoing regarding specific transaction plans[18]. - The company has engaged intermediary institutions for the major asset restructuring, ensuring compliance with legal and regulatory requirements for information disclosure[18]. - The company is focusing on improving cash flow management and reducing operational costs in response to the declining cash flow figures[35]. Other Financial Metrics - The weighted average return on net assets was 0.30%, down 0.94% year-on-year[7]. - Other income grew by 105.68% year-on-year, primarily due to an increase in government subsidies received[13]. - The company experienced a 561.87% increase in fair value losses compared to the same period last year, attributed to changes in the fair value of payable equity from minority shareholders[13]. - Research and development expenses for the current period are ¥37,669,721.48, down from ¥48,647,713.09 in the previous period[29]. - Financial expenses for the current period are ¥467,180,747.40, a decrease from ¥634,327,177.36 in the previous period[29]. - The company did not conduct an audit for the Q3 report, which may affect the reliability of the financial data presented[39].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 18,121,348,433.23, a decrease of 10.46% compared to the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 113,744,181.03, down 18.88% year-on-year[25]. - The net profit after deducting non-recurring gains and losses was CNY 98,253,816.58, reflecting a decline of 25.15% compared to the previous year[25]. - The net cash flow from operating activities was CNY 785,254,194.36, a decrease of 8.04% from the same period last year[25]. - The total assets at the end of the reporting period were CNY 36,629,960,235.29, down 2.59% from the end of the previous year[25]. - The net assets attributable to shareholders of the listed company increased by 1.78% to CNY 5,925,871,468.61 compared to the end of the previous year[25]. - Basic earnings per share were CNY 0.04, a decrease of 20.00% year-on-year[25]. - Diluted earnings per share were also CNY 0.04, reflecting a 20.00% decline compared to the previous year[25]. - The weighted average return on net assets was 1.92%, down 0.44% from the previous year[25]. Market Trends and Industry Insights - The pharmaceutical distribution market in China has seen a significant increase, with total sales growing from ¥150.5 billion in 2000 to ¥2,414.9 billion in 2020, marking a 15.05 times increase over 21 years[41]. - The industry is experiencing a slowdown in sales growth due to price reductions and cost control measures, with a reported growth rate of 2.4% in 2020, down 6.2 percentage points from the previous year[41]. - The Chinese government is promoting the establishment of large-scale digital pharmaceutical distribution enterprises, aiming for 1-3 companies to exceed ¥500 billion in revenue by 2025[34]. - The implementation of the "Two Invoice System" and centralized procurement policies is reshaping the pharmaceutical distribution landscape, leading to increased industry concentration[43]. - The company anticipates growth opportunities driven by the aging population and increased health service demands, particularly in the context of the "Healthy China" strategy[41]. - The market for online pharmaceutical sales has expanded significantly, especially during the COVID-19 pandemic, indicating a shift in business models and consumer acceptance[41]. Company Strategy and Operations - The company is focused on enhancing supply chain efficiency and cost optimization in response to competitive pressures from centralized procurement and third-party logistics[43]. - The company is focusing on structural adjustment, quality improvement, and efficiency enhancement to navigate the challenges posed by the pandemic and market changes[47]. - The company is enhancing its logistics capabilities and supply chain collaboration to improve service efficiency and reduce costs[46]. - The company is committed to strengthening its risk management measures to navigate the complexities of the pharmaceutical industry and ensure effective control[94]. - The company is actively researching and analyzing industry policies to preemptively respond to market changes and maintain competitiveness[90]. Research and Development - The company has invested in 22 invention patents related to generic drug consistency evaluation and new Chinese medicine research[52]. - The R&D team consists of 179 members, having completed over 30 postdoctoral research projects[52]. - The company is focused on developing new drugs for major diseases, including cancer and cardiovascular diseases, with several products in various stages of clinical research[53]. - Research and development expenses increased by 10% to support the development of innovative medical devices and technologies[171]. - The company has invested 1,000 million in R&D for new technologies to improve product efficacy and reduce costs[183]. Financial Management and Debt - The company reported a total debt of 55,700 million as of September 27, 2021, compared to 6,000 million on June 26, 2021, indicating a significant increase in liabilities[156]. - The company has a total of 10,000 million in contingent liabilities as of March 30, 2022, which is unchanged from the previous reporting period[156]. - The company has maintained a consistent level of debt with no new liabilities reported as of December 30, 2021, indicating financial stability[156]. - The company has a consistent pattern of issuing debts with two-year maturity periods, indicating a strategy for short-term financing[198]. - The company has engaged in multiple debt issuances, reflecting its ongoing financing needs and potential market expansion strategies[198]. Social Responsibility and Compliance - The company actively fulfilled its social responsibilities, including donations totaling 360,000 yuan for medical equipment and 13,000 yuan for anti-epidemic materials[119]. - The company has implemented strict environmental monitoring and compliance measures, with all indicators meeting legal discharge standards[112]. - The company has established an emergency response plan for environmental incidents, which was approved by experts and filed with the ecological environment authorities[113]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[117]. - The company is committed to reducing carbon emissions and has taken measures to ensure compliance with environmental regulations[118]. Future Outlook and Growth Projections - The company has projected a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion initiatives[171]. - The company is planning to expand its market presence in Southeast Asia, targeting a 25% market share within the next three years[171]. - The company has provided a future outlook with a revenue guidance of 4,000 million for the next quarter, reflecting a 20% increase from the previous quarter[177]. - Overall, the company aims for a 20% growth in net profit for the fiscal year 2022, driven by increased sales and operational efficiencies[183].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year increase of 15%[20] - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[20] - The company's operating revenue for 2021 was ¥41,053,584,128.44, representing a 2.58% increase compared to ¥40,022,495,409.13 in 2020[27] - The net profit attributable to shareholders for 2021 was ¥93,295,298.83, a significant turnaround from a loss of ¥288,531,280.73 in 2020, marking a 132.33% increase[27] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,296,820.61, up 112.71% from a loss of ¥332,778,369.00 in 2020[27] - The company achieved a revenue of approximately CNY 410.54 billion in 2021, representing a year-on-year growth of 2.58%[51] - The net profit attributable to shareholders was approximately CNY 0.93 billion, reflecting a significant year-on-year increase of 132.33%[51] - The total revenue from the top five customers amounted to ¥2,901,827,792, representing 7.07% of the annual sales[83] - The total procurement amount from the top five suppliers was ¥4,302,611,406.31, accounting for 11.77% of the annual procurement[83] User Growth and Market Expansion - User data showed a growth in active users by 25%, reaching 5 million by the end of 2021[20] - The company aims to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[20] - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by 2023[178] - User data indicates a 20% increase in active users, reaching a total of 3 million by the end of 2021[178] - Market expansion efforts have led to a 15% increase in market share in the Asia-Pacific region[197] Research and Development - Research and development expenses increased by 30%, totaling 200 million RMB, reflecting the company's commitment to innovation[20] - The R&D team consists of 137 members, having completed over 30 postdoctoral research projects, and the postdoctoral workstation is recognized as an advanced management unit by the Shenzhen government[55] - The company is committed to enhancing its R&D capabilities by focusing on small molecule chemical drugs, improved innovative drugs, traditional Chinese medicine, and marine drugs[123] - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and safety[197] Strategic Initiatives - The company plans to launch three new products in 2022, focusing on innovative drug formulations and biotechnology[20] - Future guidance indicates an expected revenue growth of 20% for 2022, driven by market expansion and new product launches[20] - The company is exploring strategic acquisitions to enhance its market position and expand its product portfolio[20] - The company plans to acquire a local competitor, which is projected to enhance market share by 5%[178] - A new strategic partnership with a leading pharmaceutical company is expected to generate an additional 100 million RMB in revenue[178] - The company is actively exploring external mergers and acquisitions to enhance its competitive edge and enter emerging industries[130] Financial Management and Governance - The company has maintained its controlling shareholder since its listing in 1998, ensuring stability in management and strategy[25] - The company emphasizes the protection of stakeholder rights and actively engages with investors through various communication channels[151] - The management team is fully responsible for operational management, effectively executing board decisions while being subject to oversight[150] - The company has a complete and independent business structure, with no competition with its controlling shareholder[154] - The company has a robust governance structure that aligns with legal and regulatory requirements, with no significant discrepancies noted[153] Challenges and Risks - The net cash flow from operating activities decreased by 47.53% to ¥866,120,634.27 from ¥1,650,554,959.89 in 2020[27] - The company acknowledges potential risks from macroeconomic fluctuations and is committed to enhancing its research on economic trends to mitigate these risks[119] - The company reported a goodwill value of RMB 2.329 billion as of December 31, 2021, and faces risks of impairment if future performance does not meet expectations[122] Operational Efficiency - The gross profit margin for the pharmaceutical distribution segment was 10.04%, down by 0.90% compared to the previous year[72] - The company has implemented cost-cutting measures that are anticipated to save 50 million RMB annually[178] - The company is committed to improving the management of accounts receivable, inventory, and prepaid accounts to enhance capital efficiency[137] Future Outlook - The company has outlined optimistic future projections, indicating a positive outlook for revenue growth and market expansion[171] - The company projects a revenue growth of 15% for the next fiscal year, targeting 1.725 billion RMB[178] - The company plans to enter the European market by 2023, aiming for a revenue contribution of 5% from this region[197]

Financial Performance - The company's operating revenue for Q1 2022 was ¥9,201,630,764.82, a decrease of 9.20% compared to ¥10,133,836,664.76 in the same period last year[4] - Net profit attributable to shareholders was ¥70,927,976.38, down 22.48% from ¥91,496,225.03 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0269, representing a decline of 19.22% from ¥0.0333 in the same period last year[4] - The total operating revenue for the first quarter was ¥9,201,630,764.82, a decrease of 9.2% compared to ¥10,133,836,664.76 in the previous year[26] - The total operating costs for the first quarter were ¥9,074,076,507.26, down from ¥9,934,059,742.69, reflecting a reduction of 8.7%[26] - The net profit for the current period is CNY 100,718,458.35, a decrease of 29.5% compared to CNY 143,104,341.40 in the previous period[29] - The total profit for the current period is CNY 135,094,285.04, down from CNY 208,608,437.67, reflecting a decline of 35.1%[29] - The total comprehensive income attributable to the parent company's owners is CNY 70,927,976.38, compared to CNY 90,554,667.53, a decrease of 21.7%[33] - Basic and diluted earnings per share decreased to CNY 0.0269 from CNY 0.0333, a decline of 19.3%[33] Cash Flow - The net cash flow from operating activities decreased by 56.92%, amounting to ¥167,896,816.35 compared to ¥389,753,412.22 in the previous year[4] - The cash flow from operating activities for the current period is CNY 167,896,816.35, down 57.0% from CNY 389,753,412.22 in the previous period[34] - The cash inflow from operating activities totaled CNY 9,490,023,016.36, down 6.4% from CNY 10,143,908,188.10[34] - The cash outflow from operating activities was CNY 9,322,126,200.01, a decrease of 4.4% compared to CNY 9,754,154,775.88[34] - Cash inflow from financing activities totaled approximately $4.02 billion, a decrease of 32.1% from $5.92 billion in the previous period[40] - Cash outflow from financing activities amounted to about $4.62 billion, down 19.5% from $5.74 billion year-over-year[40] - Net cash flow from financing activities was negative at approximately -$599.69 million, contrasting with a positive $182.50 million in the prior period[40] - The ending balance of cash and cash equivalents was approximately $533.01 million, a significant decrease from $1.84 billion at the end of the previous period[40] - The net increase in cash and cash equivalents was negative at -$446.82 million, compared to a positive increase of $348.26 million previously[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥36,942,029,945.71, a decrease of 1.76% from ¥37,603,849,419.61 at the end of the previous year[4] - The total assets decreased to ¥36,942,029,945.71 from ¥37,603,849,419.61, representing a decline of 1.8%[21] - The total liabilities decreased to ¥29,549,172,806.75 from ¥30,295,590,943.09, showing a reduction of 2.5%[25] - The company's inventory decreased to ¥3,521,680,864.95 from ¥3,792,908,469.56, a decline of 7.1%[18] - The cash and cash equivalents at the end of the period amounted to ¥3,742,341,870.87, down from ¥4,127,017,083.57 at the beginning of the year, indicating a decrease of 9.4%[18] - The company's total equity attributable to shareholders was ¥5,893,059,318.74, an increase of 1.22% from ¥5,822,126,598.89 at the end of the previous year[4] - The company's retained earnings increased to ¥1,056,620,320.90 from ¥985,687,601.05, marking a growth of 7.2%[25] - The long-term equity investments increased slightly to ¥390,622,871.68 from ¥385,006,728.76, reflecting a growth of 1.6%[21] Other Income and Expenses - The company's other income increased by 143.02% year-on-year, primarily due to increased pandemic-related subsidies[8] - Cash received from investment increased by 310.22% year-on-year, attributed to a rise in redeemed structured deposits[8] - Cash flow from financing activities decreased by 428.60% year-on-year, mainly due to loan repayments[8] - The company reported a decrease in investment income cash flow by 85.25% year-on-year, due to reduced dividends from joint ventures[8] - Sales expenses decreased to CNY 381,096,502.80 from CNY 409,275,813.02, a reduction of 6.5%[29] - Research and development expenses decreased to CNY 11,543,209.87 from CNY 12,835,341.47, a decline of 10.1%[29] Development and Restructuring - The company received approval for the clinical trial of "ABRJ oral microemulsion" from the National Medical Products Administration in April 2021, indicating ongoing product development efforts[14] - The company is in the planning stage for significant asset restructuring and mixed ownership reform, which carries substantial uncertainty[14] Audit Status - The company’s first quarter report was not audited[41]

Financial Performance - The company's revenue for Q3 2021 was ¥10,537,255,907.17, representing a decrease of 3.15% compared to the same period last year[4] - Net profit attributable to shareholders was ¥73,472,504.04, an increase of 1.75% year-on-year[4] - Net profit excluding non-recurring gains and losses decreased by 49.66% to ¥60,757,670.24[4] - Total operating revenue for the current period reached CNY 30,775,630,066.91, an increase of 7.07% compared to CNY 28,745,122,185.02 in the previous period[25] - Net profit for the current period was CNY 351,745,607.06, a decrease of 17.3% from CNY 425,194,981.82 in the previous period[25] - The net profit attributable to the parent company was CNY 213,690,647.41, compared to CNY 200,337,612.75 in the previous period, showing an increase of 6.7%[28] - The total comprehensive income for the current period was CNY 350,804,049.56, down from CNY 425,194,981.82 in the previous period[28] Cash Flow - Operating cash flow for the year-to-date increased significantly by 550.45% to ¥1,130,606,278.79[4] - Cash flow from operating activities increased to ¥1,130,606,278.79, compared to ¥173,819,313.43 in the previous period, representing a significant growth[32] - Cash inflow from operating activities totaled ¥35,647,916,549.00, up from ¥31,738,415,095.93 in the prior period[32] - Cash outflow for purchasing goods and services rose to ¥29,038,219,045.66, compared to ¥25,260,063,059.75 previously[32] - Net cash flow from investing activities was -¥708,547,597.51, an increase in outflow from -¥271,223,689.76 in the last period[35] - Total cash inflow from financing activities decreased to ¥17,350,468,225.70 from ¥20,176,703,830.68[35] - Cash outflow for debt repayment was ¥11,501,856,115.62, slightly down from ¥11,586,181,511.26 in the previous period[35] - The net increase in cash and cash equivalents was -¥1,031,787,153.51, compared to an increase of ¥239,051,524.32 in the last period[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥39,827,938,984.22, a slight increase of 0.27% from the end of the previous year[4] - Total current assets as of September 30, 2021, amounted to ¥33,227,275,736.62, a decrease from ¥33,629,750,978.24 at the end of 2020[19] - Total non-current assets increased to ¥6,600,663,247.60 from ¥6,090,755,548.56 year-over-year[19] - The total liabilities amounted to CNY 32,326,007,777.50, slightly up from CNY 32,230,711,212.40[22] - Current liabilities totaled approximately ¥31.87 billion, which is a significant portion of the total liabilities[41] - Non-current liabilities were reported at approximately ¥359.25 million, with a notable increase in lease liabilities to ¥284.10 million[41] - The total equity attributable to shareholders was approximately ¥5.88 billion, while total equity reached approximately ¥7.49 billion[45] Shareholder Information - Total number of common shareholders at the end of the reporting period was 170,277[12] - The largest shareholder, Shenzhen Haiwang Group, holds 44.22% of shares, totaling 1,216,445,128 shares[12] - The total equity attributable to shareholders of the parent company was CNY 5,924,245,326.29, an increase from CNY 5,878,794,515.68[22] Research and Development - The company reported a 40.63% increase in R&D expenses, reflecting increased investment in research and development[8] - Research and development expenses increased to CNY 48,647,713.09 from CNY 34,593,150.85, representing a growth of 40.6%[25] Financial Position - The company has a total of ¥2.44 billion in notes payable and ¥8.29 billion in accounts payable, reflecting substantial short-term obligations[41] - The company reported a retained earnings of approximately ¥891.45 million, indicating a strong profit retention strategy[45] - The capital reserve stands at approximately ¥2.46 billion, with treasury stock amounting to ¥275.12 million[45] - The company has a deferred income tax liability of approximately ¥2.41 million, indicating potential future tax obligations[41] Audit Status - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[46]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 20,238,374,159.74, representing a 13.28% increase compared to CNY 17,865,681,116.92 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 140,218,143.37, up 9.44% from CNY 128,125,438.13 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 131,262,075.48, reflecting a 7.27% increase from CNY 122,360,845.40 year-on-year[26]. - The net cash flow from operating activities was CNY 853,894,827.54, which is a 13.92% increase compared to CNY 749,543,031.55 in the same period last year[26]. - The basic earnings per share were CNY 0.0510, an increase of 9.91% from CNY 0.0464 in the previous year[26]. - Total assets at the end of the reporting period were CNY 40,113,330,237.05, a 0.99% increase from CNY 39,720,506,526.80 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were CNY 5,850,635,303.13, showing a decrease of 0.48% from CNY 5,878,794,515.68 at the end of the previous year[26]. - The weighted average return on net assets was 2.36%, up from 2.03% in the previous year, indicating a 0.33% increase[26]. Revenue Segmentation - The pharmaceutical commercial segment generated revenue of approximately CNY 19.84 billion, with the medical device distribution business contributing approximately CNY 4.572 billion[36]. - The pharmaceutical manufacturing segment reported revenue of approximately CNY 229 million, while the food and health products segment generated approximately CNY 103 million[37]. - The pharmaceutical distribution segment accounted for 75.44% of total revenue, with revenue of ¥15,267,795,747.75, up 15.20% year-on-year[60]. Strategic Initiatives - The company is expanding its pharmaceutical commercial network, covering over 20 provinces in China, and ranks seventh in the national pharmaceutical wholesale revenue[36]. - The company is actively pursuing innovation and has established several research and development platforms, including a national high-tech research development base[38]. - The company plans to enhance its pharmaceutical industrial layout, aiming to increase the sales proportion of its industrial products by optimizing existing product structures and leveraging its commercial network[46]. - The company is focusing on the medical device sector, seeking partnerships with leading domestic and international companies to expand market share and invest in R&D and manufacturing capabilities[46]. - The company aims to optimize its pharmaceutical sales structure by enhancing terminal distribution and establishing a dual-channel model for online and offline sales[47]. - The company is exploring the beauty and medical aesthetics industry, planning to integrate external beauty businesses and develop medical aesthetic consumables[48]. - The company is developing an intelligent logistics distribution model, leveraging AI to create a direct procurement and delivery system linking manufacturers and medical institutions[49]. Community Engagement and Social Responsibility - The company received recognition as a key enterprise in epidemic prevention and control in May 2021, highlighting its commitment to social responsibility[97]. - The company actively engages in community support and tax compliance, fulfilling its corporate social responsibilities[97]. - The company donated a total of 1,000,000 CNY in cash and goods for poverty alleviation and educational support during the reporting period[101]. - The company contributed 57,733.6 CNY worth of medicines to the Red Cross Society in May 2021 for medical outreach activities[101]. - A donation of 509,590 CNY was made to the Zhengzhou Red Cross Society in June 2021 to support national poverty alleviation efforts[101]. - The company actively participated in charity projects, including a 150,000 CNY donation to a poverty alleviation project in July 2021[101]. Governance and Compliance - The company received a regulatory correction order from the Shenzhen Securities Regulatory Bureau due to governance and internal control issues[112]. - The company has committed to rectifying the issues identified in the regulatory order and submitted a corrective report[113]. - The company’s governance structure includes direct appointments of key financial and operational roles to enhance oversight[85]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[91]. - The company has not engaged in any non-operating fund occupation by major shareholders or related parties during the reporting period[105]. - The total amount of related party transactions for the reporting period was 73,975.19 million CNY, accounting for 1.91% of similar transactions[117]. Market Trends and Challenges - The pharmaceutical distribution industry in China is experiencing increasing concentration, with the top 20 wholesale companies accounting for 63.5% of the market share, up 2 percentage points year-on-year[42]. - The company is facing risks from macroeconomic fluctuations due to the ongoing COVID-19 pandemic, which has affected the global market environment[84]. - The company is enhancing its management capabilities to address challenges posed by rapid acquisitions and resource integration[84]. - The company will continue to monitor industry dynamics and adapt to policy changes to mitigate potential risks[84]. Future Outlook - The company anticipates continued growth in the upcoming quarters, with a projected revenue increase of 20% year-over-year for the next fiscal year[139]. - The company is focusing on expanding its market presence, particularly in the medical device sector, with plans to launch new products in the next quarter[139]. - The company is investing in research and development for new technologies aimed at improving product efficiency and market competitiveness[139]. - The company is exploring strategic acquisitions to bolster its market position and enhance its product portfolio[169].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2020, representing a year-on-year increase of 15%[4] - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[4] - The company's operating revenue for 2020 was ¥40,022,495,409.13, a decrease of 3.54% compared to ¥41,492,703,945.65 in 2019[26] - The net profit attributable to shareholders was -¥288,531,280.73, representing a decline of 239.79% from ¥240,961,388.24 in the previous year[26] - The net profit after deducting non-recurring gains and losses was -¥332,778,369.00, a drop of 738.67% compared to ¥52,105,045.51 in 2019[26] - The net cash flow from operating activities decreased by 27.24% to ¥1,650,554,959.89 from ¥2,268,621,934.86 in 2019[26] - The total assets at the end of 2020 were ¥39,720,506,526.80, down 3.52% from ¥41,168,283,718.59 in 2019[27] - The net assets attributable to shareholders decreased by 6.03% to ¥5,878,794,515.68 from ¥6,254,446,734.01 in 2019[27] - The basic earnings per share for 2020 was -¥0.11, a decline of 241.03% from ¥0.091 in 2019[26] - The diluted earnings per share also stood at -¥0.11, reflecting the same percentage decrease as basic earnings per share[26] - The weighted average return on equity was -4.72%, down from 3.34% in the previous year[26] - The company achieved a total revenue of approximately CNY 400.22 billion in 2020, with a net profit attributable to shareholders of approximately CNY -2.89 billion[60] Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2022[4] - User data showed a growth of 25% in active users of the company's health products, reaching 5 million users by the end of 2020[4] - The company is exploring potential acquisitions in the biotechnology sector to enhance its product portfolio[4] - The company is actively expanding its financing channels, with a non-public stock issuance plan aiming to raise between CNY 150 million and CNY 250 million[63] - The company is focusing on optimizing its operational structure and introducing new business lines, including traditional Chinese medicine and medical devices[60] Research and Development - The company plans to invest 200 million RMB in R&D for new product development in the upcoming year[4] - The total R&D investment for the reporting period was CNY 50,495,616.40, accounting for 0.86% of the net assets attributable to shareholders and 0.13% of operating revenue[93] - The company’s R&D personnel decreased by 6.21% from 145 in 2019 to 136 in 2020, while the R&D investment capitalized amount decreased by 45.66%[94] - The company has a comprehensive technology innovation system, recognized as a national high-tech enterprise and a national-level technology center[54] - The company is leveraging modern information technology to optimize resource allocation and improve service efficiency in the pharmaceutical distribution sector[46] Operational Challenges - The pharmaceutical distribution industry is experiencing a slowdown in market sales growth due to policy impacts like centralized procurement and medical insurance cost control[42] - The industry concentration is increasing, with the top 20 wholesale companies accounting for 61.5% of the national pharmaceutical market in 2019, up 2.5 percentage points year-on-year[45] - The company is facing intensified competition in the pharmaceutical industry due to government reforms and policies, which may affect growth rates and profitability[120] - The company acknowledges that the realization of its 2021 operational plans is subject to various uncertainties influenced by internal and external factors[131] Corporate Governance and Compliance - The company has implemented a three-tier management model to effectively manage subsidiaries and ensure compliance with governance standards[124] - The actual controller and shareholders have fulfilled their commitments during the reporting period, including a commitment to avoid competition with the company's business[145] - The company guarantees compliance with relevant regulations and will not exploit its controlling position to harm the interests of other shareholders[155] - The company has established a long-term commitment to adhere to regulatory requirements and ensure transparency in its operations[181] Dividends and Shareholder Commitments - The company announced no cash dividends for the year, opting to reinvest profits into business growth[4] - The company did not distribute cash dividends for 2020 due to negative retained earnings and the impact of the COVID-19 pandemic on operations[139] - The company plans not to distribute cash dividends or issue bonus shares in the upcoming fiscal year[144] - The company reported a net profit attributable to shareholders of -288.53 million yuan for 2020, with an undistributed profit of 891.45 million yuan as of December 31, 2020[138] Acquisitions and Subsidiary Management - The company acquired 65% of Xinxiang Yinhai and 75% of Hubei Medical Equipment during the reporting period[79] - The company disposed of several subsidiaries, including Shenzhen Haiwang Food Co., Ltd. for CNY 3,160,000, and Inner Mongolia Haiwang Pharmaceutical Co., Ltd. for CNY 90,598,425, resulting in a total net asset gain of CNY 12,858,293.38 and CNY 41,949,555.83 respectively[80] - The company is currently in the process of resolving potential competition issues with its subsidiary, Haiwang Pharmaceutical, through share transfers and other legal means[185] - The company has committed to transferring the drug registration certificates of currently produced drugs to Haiwang Biological or its designated subsidiaries without charge by December 31, 2022[187]

深圳市海王生物工程股份有限公司 2021 年第一季度报告全文 深圳市海王生物工程股份有限公司 2021 年第一季度报告 2021 年 04 月 1 深圳市海王生物工程股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事局、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事局会议。 公司负责人张锋、主管会计工作负责人沈大凯及会计机构负责人(会计主管 人员)李爽声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市海王生物工程股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|---------------------------| | □ 是 ...